Background: The efficacy of medical treatment among obese men with lower urinary tract symptoms (LUTS) has been less clear, especially regarding the improvement of QoL. We aimed to investigate the difference in efficacy and consequent satisfaction of life quality after medical treatment of male LUTS according to obesity. Methods: An 8-week prospective study was performed for a total of 140 patients >50 years old with International Prostate Symptom Scores (IPSS) > 12 points and prostate volume > 20 mL. Obesity was determined by either body mass index (BMI) or waist circumference (WC). Patients were divided into 2 groups according to BMI or WC. Patients received tamsulosin at a dose of 0.4 mg daily for 8 weeks. The changes from baseline in the IPSS, maximal urinary flow rate (Qmax), post-void residual volume, questionnaire of quality of life (QoL), and King's Health Questionnaire (KHQ) were analyzed. Results: Of the 150 enrolled patients, 96 completed the study. Seventy-five patients (78.1%) had BMI ≥ 23 kg/m
Background
Benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) is a common disease entity in older men and has a negative impact on quality of life (QoL) [1] [2] [3] . Obesity is also a common condition in older males and is related to LUTS [1, 3] . As in Western countries, Korean men have a high prevalence of symptomatic BPH as they age, with a prevalence of 10.6%-31% in men > 50 years old [2, 4] . Several studies have reported a significant relationship between LUTS and obesity [3, 5, 6] . Considering the objective evidence of a negative effect of both LUTS [7] [8] [9] [10] [11] [12] [13] and obesity [14] on QoL, LUTS plus obesity may result in a greater deterioration of QoL.
Among the alpha blockers, tamsulosin is one of the most commonly recommended because of its efficacy, safety, and tolerability [15] . The King's Health Questionnaire (KHQ) is a validated tool to measure the QoL in patients with LUTS [9] . Although the KHQ was developed originally for female urge incontinence, validity has been proven in studies that dealt with LUTS and healthrelated quality of life (HRQoL) in both sexes [9, [16] [17] [18] [19] .
To date, efficacy of medical treatment among obese men with LUTS has been less clear, especially regarding the improvement of QoL within specific domains. Recently, Lee et al. [14] reported that alpha-blockers have a greater efficacy in improvement of LUTS when used in obese men. The main presumed hypothesis for this difference is that obese men have a greater level of sympathetic activity, which is suspected to be sensitive to alpha-blockers [20, 21] .
The main purpose of this preliminary study is to investigate the improvement of LUTS and QoL in different groups (obese and non-obese).
Methods

Study design
An eight-week prospective study was conducted between March 2010 and May 2011. The study was approved by the institutional review board of Soonchunhyang University Hospital.
At the initial visit, anthropometric parameters were evaluated, including weight, height, and waist circumference. Additional parameters measured included urinalysis, serum prostate-specific antigen [22] , maximal urinary flow rate (Qmax), and post-void residual volume (PVR). Transrectal ultrasonography was also performed. At the initial and final visits, the International Prostate Symptom Score (IPSS) and KHQ were measured.
BMI was calculated as the body weight in kilograms divided by the square of the height in meters. After the first evaluation, eligible patients were treated with tamsulosin at a dose of 0.4 mg for 8 weeks. At each visit, adverse events were recorded.
Serum PSA tests were performed using the automated chemiluminescent microparticle immunoassay analyzer Architect i2000 (Abbott Diagnostic Laboratories, Abbott Park, IL, USA). The prostate was measured in three dimensions by transrectal ultrasonography using an 8.0-MHz rectal probe (GE Healthcare, LOGIQ P6-PRO, Little Chalfont, UK), and prostate volume (PV) was estimated using a modification of the prolate ellipsoid formula and recorded in cm 3 (0.523 [length (cm) × width (cm) × height (cm)]).
Acquisition of questionnaire data was performed with face-to-face interviews conducted by one investigator with all study participants using a structured questionnaire. The severity of LUTS was measured using the IPSS, which is based on the American Urological Association [23] symptom index with one additional question on QoL, and is the most widely used objective assessment of LUTS.
The KHQ consists of 8 categories, including general health perceptions, impact on life, role limitations, physical/ social limitation, personal relationships, emotions, sleep/ energy, and incontinence severity measures. The KHQ has been validated in a Korean version [24] .
Subjects
A total of 150 patients who visited the Department of Urology at Soonchunhyang University and provided informed consent were included in this study. Inclusion criteria were male ≥ 40 years of age, no history of prior treatment of BPH/LUTS, total IPSS ≥ 8, prostate volume > 20 mL as determined by transrectal ultrasound, no relevant medical history, and underlying comorbidities. Exclusion criteria were history of neurogenic bladder dysfunction, history of prostate or bladder cancer, treatment history of acute or chronic urinary retention within the previous 3 months, treatment history of acute or chronic prostatitis within the previous 3 months, PSA levels > 0.10 ng/mL, and history of urinary tract infection or bladder stones.
All patients were divided into 2 groups, non-obese (BMI < 23 kg/m 2 ) and obese (BMI ≥ 23 kg/m 2 ), according to the Asia-Pacific obesity criteria [25] . For additional analysis, we also categorized patients into 2 groups based on waist circumference (WC), normal waist (≤90 cm) and central obesity (>90 cm).
Power calculation
Sample size was not calculated because its being a preliminary study.
Statistical analysis
The primary outcome measurement was the degree of change of KHQ in the two groups, and secondary outcome measurement was the degree of change of IPSS in the two groups. All data are presented as mean ± SD. Statistical analysis was performed using SPSS (version 21.0; Chicago, IL, USA). Changes from baseline in total IPSS, QoL scores, and KHQ scores were analyzed using Wilcoxon signed-rank test. A P value < 0.05 was considered significant.
Results
Of the 140 enrolled patients, 96 completed the study. Fifty four patients discontinued the trial. Of these, 22 were lost to follow-up, 14 refused to complete the final questionnaires, and 18 patients discontinued the medication because of low efficacy (9 patients) or adverse events (9 patients) ( Figure 1) .
The basic characteristics, including age, PSA, PV, Qmax, total IPSS, and KHQ questionnaire are described in Table 1 . Between the obese group (BMI ≥ 23 kg/m 2 ) and non-obese group (BMI < 23 kg/m 2 ), no significant difference occurred among the variables. Between the central obesity group (WC > 90 cm) and non-central obesity group (WC ≤ 90 cm), no significant difference occurred among the variables except age.
After 8 weeks treatment with tamsulosin, overall improvement was seen in the total IPSS and IPSS QoL (P < 0.001) ( Table 2) . Total KHQ scores also improved after treatment (P < 0.001). Among the domains, general health, impact on life, role limitations, physical limitation, emotions, sleep/energy, and incontinence severity were improved or significantly improved. However, social limitation and personal relationships did not show improvement after treatment (Table 2) .
In subgroup analysis, the non-obese group showed no improvement in total KHQ (P = 0.055) ( Table 3) . Among the KHQ domains, the obese group showed improvement only in general health (P = 0.025), impact on life (P = 0.020), and emotions (P = 0.047). The obese group showed improvement in total KHQ (P < 0.001) ( Table 3) . Among the KHQ domains, the obese group showed improvement in general health (P < 0.001), impact on life (P < 0.001), role limitations (P = 0.001), physical limitation (P < 0.001), and emotions (P < 0.001). The comparison of improvement of IPSS and KHQ revealed that obesity group showed significant greater improvement in total IPSS, physical limitation, and sleep/energy (Table 4) .
In other subgroup analysis, the non-central obesity group showed no improvement in total IPSS, IPSS QoL, and total KHQ (Table 4) . Among the KHQ domains, the non-central obesity group showed improvement only in general health (P = 0.020) and impact on life (P = 0.032). The central obesity group showed improvement in total IPSS, IPSS QoL, and total KHQ (Table 5 ). Among the KHQ domains, the central obesity group showed improvement in general health P < 0.001), impact on life (P < 0.001), role limitations (P < 0.001), physical limitation (P = 0.002), personal relationships (P = 0.029), emotions (P < 0.001), and sleep/energy (P = 0.024). The comparison of improvement of IPSS and KHQ revealed that central obesity group showed significant greater improvement in total IPSS, impact of life, and sleep/energy (Table 5 ). Adverse events were reported in 9 patients (6.0%) and included dizziness (3.3%), postural hypotension (1.3%), and gastric discomfort (1.3%).
Discussion
When obese patients with BPH have LUTS, a larger prostate is presumed to be one of the causes. The prostate grows faster in obese than in non-obese patients [26] [27] [28] .
Many clinical studies have focused on prostate size or PSA in obese patients, but few studies have focused on the treatment outcome, including QoL, in obese patients. Although several studies have used the IPSS-QoL index to present the treatment outcome in obese patients The most prominent feature of our study was use of the KHQ questionnaire, a disease-specific HRQoL instrument for the evaluation of patients with LUTS, overactive bladder, and urinary incontinence [9, [16] [17] [18] [19] . The KHQ consists of nine domains. Seven of the domains include multiple questions including role limitations, physical limitations, social limitations, personal relationships, emotions, sleep/energy, and incontinence severity measures.
Our study revealed that comparison of improvement of IPSS QoL according to BMI and WC showed no significant difference. However, the comparison of improvement KHQ including impact on life, physical limitation, impact of life, and sleep/energy showed significant difference. Although improvement of total KHQ showed no significant difference, several domains of KHQ showed significant differences.
Although some controversies exist regarding the relationship between the severity of LUTS and obesity, obese patients usually have more severe LUTS than non-obese patients [29, 30] . Possible reasons for this phenomenon are lower testosterone concentrations, lower serum globulin-binding protein levels, and greater prostate volumes in obese patients [31] , as well as increased estrogen levels and increased free and total estradiol concentrations [32, 33] . Our data demonstrate that the baseline total IPSS showed no significant difference between the obese and non-obese groups or central obesity and non-central obesity groups. This is mainly due to our lower IPSS inclusion criteria of more than 8 points total on the IPSS. We lowered the criteria for the IPSS because patients scoring higher on the IPSS could bias the results by showing more satisfaction with treatment.
Our data showed a more favorable treatment outcome in obese patients and those with central obesity. Although an improvement in the total IPSS was demonstrated in both obese and non-obese patients, the improvement in the total IPSS was only demonstrated in patients with central obesity. Improvement in total KHQ scores was demonstrated only in obese patients and patients with central obesity.
Greater estrogen levels in old age and obesity induce lower testosterone levels and may affect prostate cell growth [32] . Enlarged adipose tissue can secrete numerous hormones and proteins that influence fat metabolism [34, 35] , and leptin stimulates the cellular proliferation of BPH [36, 37] .
Besides an enlarged prostate, obese patients have increased sympathetic tone, which is suspected to be the main reason alpha blockers could have a greater impact in obese patients. Increased sympathetic tone can result in LUTS and subjective voiding complaints [19] . In particular, abdominal obesity increases the estrogen-toandrogen ratio and may increase sympathetic nervous system activity, both of which are known to influence the development of BPH and the severity of LUTS [18] . In our study, obese patients showed improvement in 5 domains of the KHQ, but central obesity patients showed improvement in 7 domains of the KHQ. This result implies that obesity, especially central obesity, which is regarded as visceral obesity, could impact treatment outcomes. The main reason for this result is that obesity, and especially visceral adiposity, is closely related to sympathetic overactivity [38, 39] . The whole body norepinephrine spillover rate is known to be quantitatively linked with waist circumference [17, 31] , and sympathetic nerve firing rates measured by microneurography have been reported to be 55% higher in men with visceral adiposity than in men with only subcutaneous obesity.
Sympathetic activity is increased in obese men and may be related to BPH/LUTS by a common link between norepinephrine and alpha-1 adrenoceptors [38, 39] . Although general improvement of LUTS and KHQ were observed in this study, the obesity and central obesity groups showed more improvement in the IPSS and KHQ.
This study has several limitations. First, the study design has a relatively short follow-up period. However, 8 weeks is sufficient to judge the clinical outcome of alpha blockers. Moreover, the KHQ is a relatively long questionnaire and takes a long time to perform, which reduces patient compliance. Although the acquisition of questionnaire was performed by one special interviewer, a lot of patients showed negative response to the KHQ in our study. The most common reason for this negative response is that it takes quite a long time. This is why we did not perform an additional KHQ at 4 weeks. Second, this study has a relatively small size. However, considering the increasing prevalence of concomitant medical diseases, the availability of eligible patients is limited. This was a pilot; a preliminary study, and subsequent prospective study is needed.
Conclusions
Obese or central obesity patients with LUTS showed a better health-related quality of life than non-obese or non-centrally obese patients with LUTS after alpha-adrenergic medication. Therefore, alpha-adrenergic medication can be recommended to obese patients with LUTS preferentially for the improvement of quality of life.
